PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
342032-2	1978	2 Fluorescence brightness due to accumulation of alpha-methylnoradrenaline was dose-dependent and was increased by the catechol-O-methyltransferase inhibitor drugs, tropolone or beta-thujaplicin (200 micrometer) but not by 3,4-dimethoxy-5-hydroxybenzoic acid (200 microgram).	beta-thujaplicin	178-194	catechol O-methyltransferase	Cavia porcellus	119-147
33628376-11	2021	Additionally, hinokitiol enhanced the nuclear translocation of MTF1 by suppressing the JNK pathway and ameliorated the progression of IVDD in vivo.	beta-thujaplicin	14-24	metal regulatory transcription factor 1	Homo sapiens	63-67
34055782-7	2021	Importantly, preeclamptic pMSCs had less total and labile Fe2+ and Hinokitiol treatment rescued fibronectin assembly and promoted lysosomal degradation.	beta-thujaplicin	67-77	fibronectin 1	Homo sapiens	96-107
33831806-0	2021	Hinokitiol inhibits RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced bone loss in vivo.	beta-thujaplicin	0-10	TNF superfamily member 11	Homo sapiens	20-25
33831806-3	2021	In this study, hinokitiol, a tropolone-related compound extracted from the heart wood of several cupressaceous plants, was found to inhibit RANKL-induced osteoclast formation and bone resorption in vitro.	beta-thujaplicin	15-25	TNF superfamily member 11	Homo sapiens	140-145
33831806-4	2021	Hinokitiol inhibited early activation of the ERK, p38, and JNK-MAPK pathways, thereby suppressing the activity and expression of downstream factors (c-Jun, c-Fos, and NFATC1).	beta-thujaplicin	0-10	mitogen-activated protein kinase 1	Homo sapiens	45-48
33831806-4	2021	Hinokitiol inhibited early activation of the ERK, p38, and JNK-MAPK pathways, thereby suppressing the activity and expression of downstream factors (c-Jun, c-Fos, and NFATC1).	beta-thujaplicin	0-10	mitogen-activated protein kinase 14	Homo sapiens	50-53
33831806-4	2021	Hinokitiol inhibited early activation of the ERK, p38, and JNK-MAPK pathways, thereby suppressing the activity and expression of downstream factors (c-Jun, c-Fos, and NFATC1).	beta-thujaplicin	0-10	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	149-154
33831806-4	2021	Hinokitiol inhibited early activation of the ERK, p38, and JNK-MAPK pathways, thereby suppressing the activity and expression of downstream factors (c-Jun, c-Fos, and NFATC1).	beta-thujaplicin	0-10	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	156-161
33831806-4	2021	Hinokitiol inhibited early activation of the ERK, p38, and JNK-MAPK pathways, thereby suppressing the activity and expression of downstream factors (c-Jun, c-Fos, and NFATC1).	beta-thujaplicin	0-10	nuclear factor of activated T cells 1	Homo sapiens	167-173
33628376-11	2021	Additionally, hinokitiol enhanced the nuclear translocation of MTF1 by suppressing the JNK pathway and ameliorated the progression of IVDD in vivo.	beta-thujaplicin	14-24	mitogen-activated protein kinase 8	Homo sapiens	87-90
33012507-8	2020	Supplementation of zinc together with clioquinol or hinokitiol conferred a limited but observable rescue upon dZnT1 loss.	beta-thujaplicin	52-62	Zinc transporter 63C	Drosophila melanogaster	110-115
32917321-0	2020	Hinokitiol induces cell death and inhibits epidermal growth factor-induced cell migration and signaling pathways in human cervical adenocarcinoma.	beta-thujaplicin	0-10	epidermal growth factor	Homo sapiens	43-66
32917321-5	2020	The effects of hinokitiol on EGF-induced cell migration were determined by wound healing and transwell migration assays.	beta-thujaplicin	15-25	epidermal growth factor	Homo sapiens	29-32
32917321-9	2020	Western blot analysis further demonstrated that hinokitiol treatment increased the levels of p53 and p21, and concomitantly reduced the expression of cell cycle regulatory proteins, including cyclin D and cyclin E. SA-beta-gal assay showed that hinokitiol treatment significantly induced beta-galactosidase activity.	beta-thujaplicin	48-58	tumor protein p53	Homo sapiens	93-96
32917321-9	2020	Western blot analysis further demonstrated that hinokitiol treatment increased the levels of p53 and p21, and concomitantly reduced the expression of cell cycle regulatory proteins, including cyclin D and cyclin E. SA-beta-gal assay showed that hinokitiol treatment significantly induced beta-galactosidase activity.	beta-thujaplicin	48-58	H3 histone pseudogene 16	Homo sapiens	101-104
32917321-10	2020	In addition, treatment with hinokitiol increased the accumulation of the autophagy regulators, beclin 1 and microtubule-associated protein 1 light chain 3 (LC3-II), in a dose-dependent manner; however, it did not induce caspase-3 activation and poly ADP ribose polymerase (PARP) cleavage.	beta-thujaplicin	28-38	beclin 1	Homo sapiens	95-103
32917321-10	2020	In addition, treatment with hinokitiol increased the accumulation of the autophagy regulators, beclin 1 and microtubule-associated protein 1 light chain 3 (LC3-II), in a dose-dependent manner; however, it did not induce caspase-3 activation and poly ADP ribose polymerase (PARP) cleavage.	beta-thujaplicin	28-38	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	156-159
32917321-10	2020	In addition, treatment with hinokitiol increased the accumulation of the autophagy regulators, beclin 1 and microtubule-associated protein 1 light chain 3 (LC3-II), in a dose-dependent manner; however, it did not induce caspase-3 activation and poly ADP ribose polymerase (PARP) cleavage.	beta-thujaplicin	28-38	poly(ADP-ribose) polymerase 1	Homo sapiens	245-271
32917321-10	2020	In addition, treatment with hinokitiol increased the accumulation of the autophagy regulators, beclin 1 and microtubule-associated protein 1 light chain 3 (LC3-II), in a dose-dependent manner; however, it did not induce caspase-3 activation and poly ADP ribose polymerase (PARP) cleavage.	beta-thujaplicin	28-38	poly(ADP-ribose) polymerase 1	Homo sapiens	273-277
32917321-11	2020	In addition, epidermal growth factor-induced cell migration and c-Jun N-terminal kinase (JNK) and focal adhesion kinase (FAK) phosphorylation were significantly inhibited by hinokitiol.	beta-thujaplicin	174-184	epidermal growth factor	Homo sapiens	13-36
32917321-11	2020	In addition, epidermal growth factor-induced cell migration and c-Jun N-terminal kinase (JNK) and focal adhesion kinase (FAK) phosphorylation were significantly inhibited by hinokitiol.	beta-thujaplicin	174-184	mitogen-activated protein kinase 8	Homo sapiens	64-87
32917321-11	2020	In addition, epidermal growth factor-induced cell migration and c-Jun N-terminal kinase (JNK) and focal adhesion kinase (FAK) phosphorylation were significantly inhibited by hinokitiol.	beta-thujaplicin	174-184	mitogen-activated protein kinase 8	Homo sapiens	89-92
32917321-11	2020	In addition, epidermal growth factor-induced cell migration and c-Jun N-terminal kinase (JNK) and focal adhesion kinase (FAK) phosphorylation were significantly inhibited by hinokitiol.	beta-thujaplicin	174-184	protein tyrosine kinase 2	Homo sapiens	98-119
32917321-11	2020	In addition, epidermal growth factor-induced cell migration and c-Jun N-terminal kinase (JNK) and focal adhesion kinase (FAK) phosphorylation were significantly inhibited by hinokitiol.	beta-thujaplicin	174-184	protein tyrosine kinase 2	Homo sapiens	121-124
30874538-7	2019	We also found that increased expression of p21 and decreased expression of CDK7, Cyclin D1, and Cyclin A2 participating in beta-Thujaplicin caused the S-phase arrest.	beta-thujaplicin	123-139	cyclin dependent kinase 7	Homo sapiens	75-79
31026007-0	2019	beta-Thujaplicin inhibits basal-like mammary tumor growth by regulating glycogen synthase kinase-3beta/beta-catenin signaling.	beta-thujaplicin	0-16	glycogen synthase kinase 3 beta	Homo sapiens	72-102
31026007-0	2019	beta-Thujaplicin inhibits basal-like mammary tumor growth by regulating glycogen synthase kinase-3beta/beta-catenin signaling.	beta-thujaplicin	0-16	catenin beta 1	Homo sapiens	103-115
31026007-3	2019	Here, we investigated the effect of beta-thujaplicin on inhibiting ER-negative basal-like breast cancer and the underlying mechanism of action using an in vitro and in vivo xenograft animal model.	beta-thujaplicin	36-52	estrogen receptor 1	Homo sapiens	67-69
31026007-4	2019	beta-Thujaplicin induced G0/G1 phase cell cycle arrest and regulated cell cycle mediators, cyclin D1, cyclin E, and cyclin-dependent kinase 4 (CDK 4), leading to the inhibition of the proliferation of ER-negative basal-like MCF10DCIS.com human breast cancer cells.	beta-thujaplicin	0-16	cyclin D1	Homo sapiens	91-100
31026007-4	2019	beta-Thujaplicin induced G0/G1 phase cell cycle arrest and regulated cell cycle mediators, cyclin D1, cyclin E, and cyclin-dependent kinase 4 (CDK 4), leading to the inhibition of the proliferation of ER-negative basal-like MCF10DCIS.com human breast cancer cells.	beta-thujaplicin	0-16	cyclin dependent kinase 4	Homo sapiens	116-141
31026007-4	2019	beta-Thujaplicin induced G0/G1 phase cell cycle arrest and regulated cell cycle mediators, cyclin D1, cyclin E, and cyclin-dependent kinase 4 (CDK 4), leading to the inhibition of the proliferation of ER-negative basal-like MCF10DCIS.com human breast cancer cells.	beta-thujaplicin	0-16	cyclin dependent kinase 4	Homo sapiens	143-148
31026007-4	2019	beta-Thujaplicin induced G0/G1 phase cell cycle arrest and regulated cell cycle mediators, cyclin D1, cyclin E, and cyclin-dependent kinase 4 (CDK 4), leading to the inhibition of the proliferation of ER-negative basal-like MCF10DCIS.com human breast cancer cells.	beta-thujaplicin	0-16	estrogen receptor 1	Homo sapiens	201-203
31026007-6	2019	In an MCF10DCIS.com xenograft animal model, beta-thujaplicin significantly inhibited tumor growth, reduced tumor weight, and regulated the expression of cell cycle proteins, phosphorylation of AKT and GSK-3beta, and protein level of beta-catenin in the tumor tissues.	beta-thujaplicin	44-60	AKT serine/threonine kinase 1	Homo sapiens	193-196
31026007-6	2019	In an MCF10DCIS.com xenograft animal model, beta-thujaplicin significantly inhibited tumor growth, reduced tumor weight, and regulated the expression of cell cycle proteins, phosphorylation of AKT and GSK-3beta, and protein level of beta-catenin in the tumor tissues.	beta-thujaplicin	44-60	glycogen synthase kinase 3 alpha	Homo sapiens	201-210
31026007-6	2019	In an MCF10DCIS.com xenograft animal model, beta-thujaplicin significantly inhibited tumor growth, reduced tumor weight, and regulated the expression of cell cycle proteins, phosphorylation of AKT and GSK-3beta, and protein level of beta-catenin in the tumor tissues.	beta-thujaplicin	44-60	catenin beta 1	Homo sapiens	233-245
31026007-7	2019	These results demonstrate that beta-thujaplicin can suppress basal-like mammary tumor growth by regulating GSK-3beta/beta-catenin signaling, suggesting that beta-thujaplicin may be a potent chemopreventive agent against the basal-like subtype of breast cancer.	beta-thujaplicin	31-47	glycogen synthase kinase 3 alpha	Homo sapiens	107-116
31026007-7	2019	These results demonstrate that beta-thujaplicin can suppress basal-like mammary tumor growth by regulating GSK-3beta/beta-catenin signaling, suggesting that beta-thujaplicin may be a potent chemopreventive agent against the basal-like subtype of breast cancer.	beta-thujaplicin	31-47	catenin beta 1	Homo sapiens	117-129
31026007-7	2019	These results demonstrate that beta-thujaplicin can suppress basal-like mammary tumor growth by regulating GSK-3beta/beta-catenin signaling, suggesting that beta-thujaplicin may be a potent chemopreventive agent against the basal-like subtype of breast cancer.	beta-thujaplicin	157-173	glycogen synthase kinase 3 alpha	Homo sapiens	107-116
31026007-7	2019	These results demonstrate that beta-thujaplicin can suppress basal-like mammary tumor growth by regulating GSK-3beta/beta-catenin signaling, suggesting that beta-thujaplicin may be a potent chemopreventive agent against the basal-like subtype of breast cancer.	beta-thujaplicin	157-173	catenin beta 1	Homo sapiens	117-129
30569287-0	2019	Hinokitiol Offers Neuroprotection Against 6-OHDA-Induced Toxicity in SH-SY5Y Neuroblastoma Cells by Downregulating mRNA Expression of MAO/alpha-Synuclein/LRRK2/PARK7/PINK1/PTEN Genes.	beta-thujaplicin	0-10	synuclein alpha	Homo sapiens	138-153
30569287-0	2019	Hinokitiol Offers Neuroprotection Against 6-OHDA-Induced Toxicity in SH-SY5Y Neuroblastoma Cells by Downregulating mRNA Expression of MAO/alpha-Synuclein/LRRK2/PARK7/PINK1/PTEN Genes.	beta-thujaplicin	0-10	leucine rich repeat kinase 2	Homo sapiens	154-159
30569287-0	2019	Hinokitiol Offers Neuroprotection Against 6-OHDA-Induced Toxicity in SH-SY5Y Neuroblastoma Cells by Downregulating mRNA Expression of MAO/alpha-Synuclein/LRRK2/PARK7/PINK1/PTEN Genes.	beta-thujaplicin	0-10	Parkinsonism associated deglycase	Homo sapiens	160-165
30569287-0	2019	Hinokitiol Offers Neuroprotection Against 6-OHDA-Induced Toxicity in SH-SY5Y Neuroblastoma Cells by Downregulating mRNA Expression of MAO/alpha-Synuclein/LRRK2/PARK7/PINK1/PTEN Genes.	beta-thujaplicin	0-10	PTEN induced kinase 1	Homo sapiens	166-171
30569287-0	2019	Hinokitiol Offers Neuroprotection Against 6-OHDA-Induced Toxicity in SH-SY5Y Neuroblastoma Cells by Downregulating mRNA Expression of MAO/alpha-Synuclein/LRRK2/PARK7/PINK1/PTEN Genes.	beta-thujaplicin	0-10	phosphatase and tensin homolog	Homo sapiens	172-176
30569287-5	2019	Hence, in this study, we have examined the effect of hinokitol to act as a neuroprotective agent against 6-OHDA-induced toxicity in SH-SY5Y neuroblastoma cells through downregulation of the mRNA expression of PD pathological proteins like alpha-synuclein, MAO A and B, LRRK2, PTEN, PINK1, and PARK7 (deglycase 1 (DJ-1)).	beta-thujaplicin	53-62	synuclein alpha	Homo sapiens	239-254
30569287-5	2019	Hence, in this study, we have examined the effect of hinokitol to act as a neuroprotective agent against 6-OHDA-induced toxicity in SH-SY5Y neuroblastoma cells through downregulation of the mRNA expression of PD pathological proteins like alpha-synuclein, MAO A and B, LRRK2, PTEN, PINK1, and PARK7 (deglycase 1 (DJ-1)).	beta-thujaplicin	53-62	monoamine oxidase A	Homo sapiens	256-267
30569287-5	2019	Hence, in this study, we have examined the effect of hinokitol to act as a neuroprotective agent against 6-OHDA-induced toxicity in SH-SY5Y neuroblastoma cells through downregulation of the mRNA expression of PD pathological proteins like alpha-synuclein, MAO A and B, LRRK2, PTEN, PINK1, and PARK7 (deglycase 1 (DJ-1)).	beta-thujaplicin	53-62	leucine rich repeat kinase 2	Homo sapiens	269-274
30569287-5	2019	Hence, in this study, we have examined the effect of hinokitol to act as a neuroprotective agent against 6-OHDA-induced toxicity in SH-SY5Y neuroblastoma cells through downregulation of the mRNA expression of PD pathological proteins like alpha-synuclein, MAO A and B, LRRK2, PTEN, PINK1, and PARK7 (deglycase 1 (DJ-1)).	beta-thujaplicin	53-62	phosphatase and tensin homolog	Homo sapiens	276-280
30569287-5	2019	Hence, in this study, we have examined the effect of hinokitol to act as a neuroprotective agent against 6-OHDA-induced toxicity in SH-SY5Y neuroblastoma cells through downregulation of the mRNA expression of PD pathological proteins like alpha-synuclein, MAO A and B, LRRK2, PTEN, PINK1, and PARK7 (deglycase 1 (DJ-1)).	beta-thujaplicin	53-62	PTEN induced kinase 1	Homo sapiens	282-287
30569287-5	2019	Hence, in this study, we have examined the effect of hinokitol to act as a neuroprotective agent against 6-OHDA-induced toxicity in SH-SY5Y neuroblastoma cells through downregulation of the mRNA expression of PD pathological proteins like alpha-synuclein, MAO A and B, LRRK2, PTEN, PINK1, and PARK7 (deglycase 1 (DJ-1)).	beta-thujaplicin	53-62	Parkinsonism associated deglycase	Homo sapiens	293-298
30569287-5	2019	Hence, in this study, we have examined the effect of hinokitol to act as a neuroprotective agent against 6-OHDA-induced toxicity in SH-SY5Y neuroblastoma cells through downregulation of the mRNA expression of PD pathological proteins like alpha-synuclein, MAO A and B, LRRK2, PTEN, PINK1, and PARK7 (deglycase 1 (DJ-1)).	beta-thujaplicin	53-62	Parkinsonism associated deglycase	Homo sapiens	313-317
30874538-5	2019	Further using beta-Thujaplicin combined with an autophagy blocker or agonist treatment HepG2 cells, we found that beta-Thujaplicin induced autophagic cell death (ACD) mediated by ROS caused inhibition of the Akt-mTOR signaling pathway.	beta-thujaplicin	114-130	AKT serine/threonine kinase 1	Homo sapiens	208-211
30874538-6	2019	Moreover, beta-Thujaplicin triggered HepG2 apoptosis and increased cleaved PARP1, cleaved caspase-3, and Bax/Bcl-2 ratio, which indicated that beta-Thujaplicin induced apoptosis mediated by the mitochondrial-dependent pathway.	beta-thujaplicin	10-26	poly(ADP-ribose) polymerase 1	Homo sapiens	75-80
30874538-6	2019	Moreover, beta-Thujaplicin triggered HepG2 apoptosis and increased cleaved PARP1, cleaved caspase-3, and Bax/Bcl-2 ratio, which indicated that beta-Thujaplicin induced apoptosis mediated by the mitochondrial-dependent pathway.	beta-thujaplicin	10-26	BCL2 associated X, apoptosis regulator	Homo sapiens	105-108
30874538-6	2019	Moreover, beta-Thujaplicin triggered HepG2 apoptosis and increased cleaved PARP1, cleaved caspase-3, and Bax/Bcl-2 ratio, which indicated that beta-Thujaplicin induced apoptosis mediated by the mitochondrial-dependent pathway.	beta-thujaplicin	10-26	BCL2 apoptosis regulator	Homo sapiens	109-114
30874538-6	2019	Moreover, beta-Thujaplicin triggered HepG2 apoptosis and increased cleaved PARP1, cleaved caspase-3, and Bax/Bcl-2 ratio, which indicated that beta-Thujaplicin induced apoptosis mediated by the mitochondrial-dependent pathway.	beta-thujaplicin	143-159	poly(ADP-ribose) polymerase 1	Homo sapiens	75-80
30874538-6	2019	Moreover, beta-Thujaplicin triggered HepG2 apoptosis and increased cleaved PARP1, cleaved caspase-3, and Bax/Bcl-2 ratio, which indicated that beta-Thujaplicin induced apoptosis mediated by the mitochondrial-dependent pathway.	beta-thujaplicin	143-159	BCL2 associated X, apoptosis regulator	Homo sapiens	105-108
30874538-6	2019	Moreover, beta-Thujaplicin triggered HepG2 apoptosis and increased cleaved PARP1, cleaved caspase-3, and Bax/Bcl-2 ratio, which indicated that beta-Thujaplicin induced apoptosis mediated by the mitochondrial-dependent pathway.	beta-thujaplicin	143-159	BCL2 apoptosis regulator	Homo sapiens	109-114
30874538-7	2019	We also found that increased expression of p21 and decreased expression of CDK7, Cyclin D1, and Cyclin A2 participating in beta-Thujaplicin caused the S-phase arrest.	beta-thujaplicin	123-139	cyclin D1	Homo sapiens	81-90
30874538-7	2019	We also found that increased expression of p21 and decreased expression of CDK7, Cyclin D1, and Cyclin A2 participating in beta-Thujaplicin caused the S-phase arrest.	beta-thujaplicin	123-139	cyclin A2	Homo sapiens	96-105
29765446-0	2018	Inhibitory effect of PDGF-BB and serum-stimulated responses in vascular smooth muscle cell proliferation by hinokitiol via up-regulation of p21 and p53.	beta-thujaplicin	108-118	KRAS proto-oncogene, GTPase	Rattus norvegicus	140-143
30714720-8	2019	The catalytic activity of enolase was effectively inhibited by both the naturally occurring beta-thujaplicin and the alpha- and beta-substituted phenyl derivatives of tropolones with IC50 values in range of 8-11 muM.	beta-thujaplicin	92-108	Enolase	Escherichia coli	26-33
30548082-7	2019	Hinokitiol could inhibited NF-kappaB activation and IL-6 and TNF-alpha upregulation in liver tissues.	beta-thujaplicin	0-10	nuclear factor kappa B subunit 1	Homo sapiens	27-36
30548082-7	2019	Hinokitiol could inhibited NF-kappaB activation and IL-6 and TNF-alpha upregulation in liver tissues.	beta-thujaplicin	0-10	interleukin 6	Homo sapiens	52-56
30548082-7	2019	Hinokitiol could inhibited NF-kappaB activation and IL-6 and TNF-alpha upregulation in liver tissues.	beta-thujaplicin	0-10	tumor necrosis factor	Homo sapiens	61-70
30548082-8	2019	Moreover, hinokitiol reduced caspase-3 activation, upregulated Bax and downregulated Bcl-2.	beta-thujaplicin	10-20	caspase 3	Homo sapiens	29-38
30548082-8	2019	Moreover, hinokitiol reduced caspase-3 activation, upregulated Bax and downregulated Bcl-2.	beta-thujaplicin	10-20	BCL2 associated X, apoptosis regulator	Homo sapiens	63-66
30548082-8	2019	Moreover, hinokitiol reduced caspase-3 activation, upregulated Bax and downregulated Bcl-2.	beta-thujaplicin	10-20	BCL2 apoptosis regulator	Homo sapiens	85-90
30548082-11	2019	Hinokitiol prevented H/R-induced caspase-3 activation, PPAR cleavage, Bax overexpression and Bcl-2 downregulation.	beta-thujaplicin	0-10	caspase 3	Homo sapiens	33-42
30548082-11	2019	Hinokitiol prevented H/R-induced caspase-3 activation, PPAR cleavage, Bax overexpression and Bcl-2 downregulation.	beta-thujaplicin	0-10	peroxisome proliferator activated receptor alpha	Homo sapiens	55-59
30548082-11	2019	Hinokitiol prevented H/R-induced caspase-3 activation, PPAR cleavage, Bax overexpression and Bcl-2 downregulation.	beta-thujaplicin	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	70-73
30548082-11	2019	Hinokitiol prevented H/R-induced caspase-3 activation, PPAR cleavage, Bax overexpression and Bcl-2 downregulation.	beta-thujaplicin	0-10	BCL2 apoptosis regulator	Homo sapiens	93-98
30548082-12	2019	Moreover, hinokitiol attenuated H/R-stimulated NF-kappaB activation and reduced the levels of IL-6 and TNF-alpha mRNAs, suggesting that hinokitiol can protect hepatocytes from H/R injury.	beta-thujaplicin	10-20	nuclear factor kappa B subunit 1	Homo sapiens	47-56
30548082-12	2019	Moreover, hinokitiol attenuated H/R-stimulated NF-kappaB activation and reduced the levels of IL-6 and TNF-alpha mRNAs, suggesting that hinokitiol can protect hepatocytes from H/R injury.	beta-thujaplicin	10-20	interleukin 6	Homo sapiens	94-98
30548082-12	2019	Moreover, hinokitiol attenuated H/R-stimulated NF-kappaB activation and reduced the levels of IL-6 and TNF-alpha mRNAs, suggesting that hinokitiol can protect hepatocytes from H/R injury.	beta-thujaplicin	10-20	tumor necrosis factor	Homo sapiens	103-112
30548082-12	2019	Moreover, hinokitiol attenuated H/R-stimulated NF-kappaB activation and reduced the levels of IL-6 and TNF-alpha mRNAs, suggesting that hinokitiol can protect hepatocytes from H/R injury.	beta-thujaplicin	136-146	interleukin 6	Homo sapiens	94-98
30548082-12	2019	Moreover, hinokitiol attenuated H/R-stimulated NF-kappaB activation and reduced the levels of IL-6 and TNF-alpha mRNAs, suggesting that hinokitiol can protect hepatocytes from H/R injury.	beta-thujaplicin	136-146	tumor necrosis factor	Homo sapiens	103-112
30548082-13	2019	Collectively, our data suggest that hinokitiol attenuates liver injury following HS/R, partly through the inhibition of NF-kappaB activation.	beta-thujaplicin	36-46	nuclear factor kappa B subunit 1	Homo sapiens	120-129
30684529-0	2019	Hinokitiol suppresses growth of B16 melanoma by activating ERK/MKP3/proteosome pathway to downregulate survivin expression.	beta-thujaplicin	0-10	mitogen-activated protein kinase 1	Homo sapiens	59-62
30684529-0	2019	Hinokitiol suppresses growth of B16 melanoma by activating ERK/MKP3/proteosome pathway to downregulate survivin expression.	beta-thujaplicin	0-10	dual specificity phosphatase 6	Homo sapiens	63-67
30684529-8	2019	Hinokitiol rapidly induced ERK phosphorylation followed by a sustained dephosphorylation, which accompanied with an increase in expression of tumor suppressor MKP-3 (mitogen-activated protein kinase phosphatase-3).	beta-thujaplicin	0-10	mitogen-activated protein kinase 1	Homo sapiens	27-30
30684529-8	2019	Hinokitiol rapidly induced ERK phosphorylation followed by a sustained dephosphorylation, which accompanied with an increase in expression of tumor suppressor MKP-3 (mitogen-activated protein kinase phosphatase-3).	beta-thujaplicin	0-10	dual specificity phosphatase 6	Homo sapiens	159-164
30684529-8	2019	Hinokitiol rapidly induced ERK phosphorylation followed by a sustained dephosphorylation, which accompanied with an increase in expression of tumor suppressor MKP-3 (mitogen-activated protein kinase phosphatase-3).	beta-thujaplicin	0-10	dual specificity phosphatase 6	Homo sapiens	166-212
30684529-9	2019	Inhibition of hinokitiol-induced ERK activation by MEK inhibitor U0126 completely blocked expression of MKP-3.	beta-thujaplicin	14-24	mitogen-activated protein kinase 1	Homo sapiens	33-36
30684529-9	2019	Inhibition of hinokitiol-induced ERK activation by MEK inhibitor U0126 completely blocked expression of MKP-3.	beta-thujaplicin	14-24	mitogen-activated protein kinase kinase 7	Homo sapiens	51-54
30684529-9	2019	Inhibition of hinokitiol-induced ERK activation by MEK inhibitor U0126 completely blocked expression of MKP-3.	beta-thujaplicin	14-24	dual specificity phosphatase 6	Homo sapiens	104-109
30684529-10	2019	More importantly, inhibition of MKP-3 activity by NSC 95397 significantly inhibited hinokitiol-induced ERK dephosphorylation, ubiquitination and downregulation of survivin.	beta-thujaplicin	84-94	dual specificity phosphatase 6	Homo sapiens	32-37
30684529-10	2019	More importantly, inhibition of MKP-3 activity by NSC 95397 significantly inhibited hinokitiol-induced ERK dephosphorylation, ubiquitination and downregulation of survivin.	beta-thujaplicin	84-94	mitogen-activated protein kinase 1	Homo sapiens	103-106
30684529-11	2019	These results suggested that hinokitiol inhibited growth of B16-F10 melanoma through downregulation of survivin by activating ERK/MKP-3/proteosome pathway.	beta-thujaplicin	29-39	mitogen-activated protein kinase 1	Homo sapiens	126-129
30684529-11	2019	These results suggested that hinokitiol inhibited growth of B16-F10 melanoma through downregulation of survivin by activating ERK/MKP-3/proteosome pathway.	beta-thujaplicin	29-39	dual specificity phosphatase 6	Homo sapiens	130-135
30761254-5	2019	Although an antitransferrin receptor 1 (TfR1) monoclonal antibody inhibited both enucleation and hemoglobin synthesis promoted by holo-Tf, it inhibited only enucleation, but not hemoglobin synthesis, promoted by hinokitiol plus iron.	beta-thujaplicin	212-222	transferrin receptor	Mus musculus	40-44
29765446-0	2018	Inhibitory effect of PDGF-BB and serum-stimulated responses in vascular smooth muscle cell proliferation by hinokitiol via up-regulation of p21 and p53.	beta-thujaplicin	108-118	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	148-151
29765446-12	2018	Furthermore, hinokitiol augmented p53 protein phosphorylation and subsequently led to enhanced p53 activity.	beta-thujaplicin	13-23	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	34-37
29765446-12	2018	Furthermore, hinokitiol augmented p53 protein phosphorylation and subsequently led to enhanced p53 activity.	beta-thujaplicin	13-23	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	95-98
29112893-6	2017	We further demonstrated that beta-thujaplicin inhibits HR repair by reducing the recruitment of a key HR repair protein, Rad51, to DNA double-strand breaks.	beta-thujaplicin	29-45	RAD51 recombinase	Homo sapiens	121-126
29565268-0	2018	Hinokitiol Inhibits Migration of A549 Lung Cancer Cells via Suppression of MMPs and Induction of Antioxidant Enzymes and Apoptosis.	beta-thujaplicin	0-10	matrix metallopeptidase 2	Homo sapiens	75-79
29565268-7	2018	A dose-dependent inhibition of activated caspase-9 and -3 was observed in the presence of hinokitiol.	beta-thujaplicin	90-100	caspase 9	Homo sapiens	41-57
29565268-8	2018	An observed increase in protein expression of matrix metalloproteinases (MMPs) -2/-9 in A549 cells was significantly inhibited by hinokitiol.	beta-thujaplicin	130-140	matrix metallopeptidase 2	Homo sapiens	73-77
29565268-9	2018	Remarkably, when A549 cells were subjected to hinokitiol (1-5 microM), there was an increase in the activities of antioxidant enzymes catalase (CAT) and superoxide dismutase (SOD) from the reduction in cells.	beta-thujaplicin	46-56	superoxide dismutase 1	Homo sapiens	153-173
29565268-9	2018	Remarkably, when A549 cells were subjected to hinokitiol (1-5 microM), there was an increase in the activities of antioxidant enzymes catalase (CAT) and superoxide dismutase (SOD) from the reduction in cells.	beta-thujaplicin	46-56	superoxide dismutase 1	Homo sapiens	175-178
29565268-11	2018	These observations indicate that hinokitiol inhibited the migration of lung cancer A549 cells through several mechanisms, including the activation of caspases-9 and -3, induction of p53/Bax and antioxidant CAT and SOD, and reduction of MMP-2 and -9 activities.	beta-thujaplicin	33-43	caspase 9	Homo sapiens	150-167
29565268-11	2018	These observations indicate that hinokitiol inhibited the migration of lung cancer A549 cells through several mechanisms, including the activation of caspases-9 and -3, induction of p53/Bax and antioxidant CAT and SOD, and reduction of MMP-2 and -9 activities.	beta-thujaplicin	33-43	tumor protein p53	Homo sapiens	182-185
29565268-11	2018	These observations indicate that hinokitiol inhibited the migration of lung cancer A549 cells through several mechanisms, including the activation of caspases-9 and -3, induction of p53/Bax and antioxidant CAT and SOD, and reduction of MMP-2 and -9 activities.	beta-thujaplicin	33-43	BCL2 associated X, apoptosis regulator	Homo sapiens	186-189
29565268-11	2018	These observations indicate that hinokitiol inhibited the migration of lung cancer A549 cells through several mechanisms, including the activation of caspases-9 and -3, induction of p53/Bax and antioxidant CAT and SOD, and reduction of MMP-2 and -9 activities.	beta-thujaplicin	33-43	superoxide dismutase 1	Homo sapiens	214-217
29565268-11	2018	These observations indicate that hinokitiol inhibited the migration of lung cancer A549 cells through several mechanisms, including the activation of caspases-9 and -3, induction of p53/Bax and antioxidant CAT and SOD, and reduction of MMP-2 and -9 activities.	beta-thujaplicin	33-43	matrix metallopeptidase 2	Homo sapiens	236-248
29288721-8	2018	Results showed that the conditioned medium induced E-selectin and ICAM were significantly prevented by beta-thujaplicin.	beta-thujaplicin	103-119	selectin E	Homo sapiens	51-61
29288721-10	2018	Both concentrations of beta-thujaplicin also significantly prevented DEHP-induced MMP-2 and MMP-9 expression and activities.	beta-thujaplicin	23-39	matrix metallopeptidase 2	Homo sapiens	82-87
29288721-10	2018	Both concentrations of beta-thujaplicin also significantly prevented DEHP-induced MMP-2 and MMP-9 expression and activities.	beta-thujaplicin	23-39	matrix metallopeptidase 9	Homo sapiens	92-97
29112893-8	2017	Additionally, beta-thujaplicin sensitizes cancer cells to PARP inhibitor in different cancer cell lines.	beta-thujaplicin	14-30	poly(ADP-ribose) polymerase 1	Homo sapiens	58-62
29112893-9	2017	Collectively, our findings for the first time identify natural compound beta-thujaplicin, which has a good biosafety profile, as a novel HR repair inhibitor with great potential to be translated into clinical applications as a sensitizer to DNA-damage-inducing treatment such as radiation and PARP inhibitor.	beta-thujaplicin	72-88	poly(ADP-ribose) polymerase 1	Homo sapiens	293-297
28241740-0	2017	Hinokitiol induces DNA demethylation via DNMT1 and UHRF1 inhibition in colon cancer cells.	beta-thujaplicin	0-10	DNA methyltransferase 1	Homo sapiens	41-46
28257794-0	2017	SIRT1, a Class III Histone Deacetylase, Regulates LPS-Induced Inflammation in Human Keratinocytes and Mediates the Anti-Inflammatory Effects of Hinokitiol.	beta-thujaplicin	144-154	sirtuin 1	Homo sapiens	0-5
28257794-3	2017	Hinokitiol treatment inhibited LPS-mediated up-regulation of proinflammatory factors including tumor necrosis factor alpha, IL-6, and prostaglandin E2 (PGE2).	beta-thujaplicin	0-10	tumor necrosis factor	Homo sapiens	95-122
28257794-3	2017	Hinokitiol treatment inhibited LPS-mediated up-regulation of proinflammatory factors including tumor necrosis factor alpha, IL-6, and prostaglandin E2 (PGE2).	beta-thujaplicin	0-10	interleukin 6	Homo sapiens	124-128
28257794-5	2017	Sirt1, a class III histone deacetylase, was up-regulated by hinokitiol treatment, and the inhibition of Sirt1 activity using a pharmacological inhibitor or genetic silencing blocked hinokitiol-mediated anti-inflammatory effects.	beta-thujaplicin	60-70	sirtuin 1	Homo sapiens	0-5
28257794-5	2017	Sirt1, a class III histone deacetylase, was up-regulated by hinokitiol treatment, and the inhibition of Sirt1 activity using a pharmacological inhibitor or genetic silencing blocked hinokitiol-mediated anti-inflammatory effects.	beta-thujaplicin	60-70	sirtuin 1	Homo sapiens	104-109
28257794-5	2017	Sirt1, a class III histone deacetylase, was up-regulated by hinokitiol treatment, and the inhibition of Sirt1 activity using a pharmacological inhibitor or genetic silencing blocked hinokitiol-mediated anti-inflammatory effects.	beta-thujaplicin	182-192	sirtuin 1	Homo sapiens	0-5
28257794-5	2017	Sirt1, a class III histone deacetylase, was up-regulated by hinokitiol treatment, and the inhibition of Sirt1 activity using a pharmacological inhibitor or genetic silencing blocked hinokitiol-mediated anti-inflammatory effects.	beta-thujaplicin	182-192	sirtuin 1	Homo sapiens	104-109
28685346-8	2017	RESULTS: We demonstrated that hinokitiol effectively inhibited the CD133 positivity and ALDH1 activity along with the reduced self-renewal, migration, invasion, and colony formation properties of GSCs.	beta-thujaplicin	30-40	prominin 1	Homo sapiens	67-72
28685346-8	2017	RESULTS: We demonstrated that hinokitiol effectively inhibited the CD133 positivity and ALDH1 activity along with the reduced self-renewal, migration, invasion, and colony formation properties of GSCs.	beta-thujaplicin	30-40	aldehyde dehydrogenase 1 family member A1	Homo sapiens	88-93
28685346-10	2017	Furthermore, we showed that administration of exogenous Nrf2 counteracted the inhibitory effect of hinokitiol on self-renewal and invasiveness of GSCs.	beta-thujaplicin	99-109	NFE2 like bZIP transcription factor 2	Homo sapiens	56-60
29100291-0	2017	Hinokitiol up-regulates miR-494-3p to suppress BMI1 expression and inhibits self-renewal of breast cancer stem/progenitor cells.	beta-thujaplicin	0-10	microRNA 494	Homo sapiens	24-31
29100291-0	2017	Hinokitiol up-regulates miR-494-3p to suppress BMI1 expression and inhibits self-renewal of breast cancer stem/progenitor cells.	beta-thujaplicin	0-10	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	47-51
29100291-4	2017	The current research revealed that hinokitiol suppressed the self-renewal capabilities of human breast CSCs (BCSCs) and inhibited the expression of BMI1 at protein level without suppressing its mRNA.	beta-thujaplicin	35-45	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	148-152
28241740-0	2017	Hinokitiol induces DNA demethylation via DNMT1 and UHRF1 inhibition in colon cancer cells.	beta-thujaplicin	0-10	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	51-56
27269503-9	2017	Generation of ROS and MDA and decreased activity of CAT, SOD, and T-AOC were also ameliorated by hinokitiol administration.	beta-thujaplicin	97-107	catalase	Homo sapiens	52-55
28381806-3	2017	In this study, we found several naturally occurring compounds (e.g., hinokitiol, escletin, and quercetin) elevate S100A3 citrullination in a human colorectal adenocarcinoma cell line (SW480).	beta-thujaplicin	69-79	S100 calcium binding protein A3	Homo sapiens	114-120
27073579-0	2016	Hinokitiol inhibits vasculogenic mimicry activity of breast cancer stem/progenitor cells through proteasome-mediated degradation of epidermal growth factor receptor.	beta-thujaplicin	0-10	epidermal growth factor receptor	Homo sapiens	132-164
28773431-0	2016	Hinokitiol-Loaded Mesoporous Calcium Silicate Nanoparticles Induce Apoptotic Cell Death through Regulation of the Function of MDR1 in Lung Adenocarcinoma Cells.	beta-thujaplicin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	126-130
26404213-7	2015	Hinokitiol inhibited the expression and activity of MMPs-2 and -9 in B16-F10 melanoma cells, as measured by western blotting and gelatin zymography, respectively.	beta-thujaplicin	0-10	matrix metallopeptidase 2	Mus musculus	52-65
26901194-0	2016	Hinokitiol Inhibits Melanogenesis via AKT/mTOR Signaling in B16F10 Mouse Melanoma Cells.	beta-thujaplicin	0-10	thymoma viral proto-oncogene 1	Mus musculus	38-41
26901194-0	2016	Hinokitiol Inhibits Melanogenesis via AKT/mTOR Signaling in B16F10 Mouse Melanoma Cells.	beta-thujaplicin	0-10	mechanistic target of rapamycin kinase	Mus musculus	42-46
26901194-3	2016	Previously, hinokitiol inhibited the production of melanin by inhibiting tyrosinase activity.	beta-thujaplicin	12-22	tyrosinase	Mus musculus	73-83
26901194-7	2016	Moreover, the phosphorylation of the protein express levels of phospho-protein kinase B (P-AKT) and phospho-mammalian targets of rapamycin (P-mTOR) were reduced after hinokitiol treatment.	beta-thujaplicin	167-177	thymoma viral proto-oncogene 1	Mus musculus	91-94
26901194-7	2016	Moreover, the phosphorylation of the protein express levels of phospho-protein kinase B (P-AKT) and phospho-mammalian targets of rapamycin (P-mTOR) were reduced after hinokitiol treatment.	beta-thujaplicin	167-177	mechanistic target of rapamycin kinase	Mus musculus	142-146
26901194-10	2016	These findings establish that hinokitiol inhibited melanogenesis through the AKT/mTOR signaling pathway.	beta-thujaplicin	30-40	thymoma viral proto-oncogene 1	Mus musculus	77-80
26901194-10	2016	These findings establish that hinokitiol inhibited melanogenesis through the AKT/mTOR signaling pathway.	beta-thujaplicin	30-40	mechanistic target of rapamycin kinase	Mus musculus	81-85
26404213-8	2015	An observed increase in protein expression of MMPs 2/9 in melanoma cells was significantly inhibited by hinokitiol.	beta-thujaplicin	104-114	matrix metallopeptidase 2	Mus musculus	46-50
26404213-9	2015	Notably, hinokitiol (1-5 muM) increased the activities of antioxidant enzymes catalase (CAT) and superoxide dismutase (SOD) from the reduction in melanoma cells.	beta-thujaplicin	9-19	catalase	Mus musculus	78-86
26404213-9	2015	Notably, hinokitiol (1-5 muM) increased the activities of antioxidant enzymes catalase (CAT) and superoxide dismutase (SOD) from the reduction in melanoma cells.	beta-thujaplicin	9-19	catalase	Mus musculus	88-91
25449038-5	2015	Hinokitiol appeared to achieve this effect by reducing the expression of MMP-1 and by suppressing the phosphorylation of mitogen- activated protein kinase (MAPK) signaling molecules such as extracellular signal-regulated kinase (ERK) 1/2, p38 MAPK and c-Jun N-terminal kinases (JNK).	beta-thujaplicin	0-10	matrix metallopeptidase 13	Mus musculus	73-78
25961161-0	2015	Antiproliferative Activity of Hinokitiol, a Tropolone Derivative, Is Mediated via the Inductions of p-JNK and p-PLCgamma1 Signaling in PDGF-BB-Stimulated Vascular Smooth Muscle Cells.	beta-thujaplicin	30-40	phospholipase C gamma 1	Homo sapiens	112-121
25961161-10	2015	Taken together, our results suggest that hinokitiol inhibits PDGF-BB-induced proliferation of VSMCs by inducing cell cycle arrest, suppressing JNK1/2 phosphorylation and PLC-gamma1, and stimulating p27kip1 expression.	beta-thujaplicin	41-51	mitogen-activated protein kinase 8	Homo sapiens	143-147
25961161-10	2015	Taken together, our results suggest that hinokitiol inhibits PDGF-BB-induced proliferation of VSMCs by inducing cell cycle arrest, suppressing JNK1/2 phosphorylation and PLC-gamma1, and stimulating p27kip1 expression.	beta-thujaplicin	41-51	phospholipase C gamma 1	Homo sapiens	170-180
25961161-10	2015	Taken together, our results suggest that hinokitiol inhibits PDGF-BB-induced proliferation of VSMCs by inducing cell cycle arrest, suppressing JNK1/2 phosphorylation and PLC-gamma1, and stimulating p27kip1 expression.	beta-thujaplicin	41-51	cyclin dependent kinase inhibitor 1B	Homo sapiens	198-205
25449038-5	2015	Hinokitiol appeared to achieve this effect by reducing the expression of MMP-1 and by suppressing the phosphorylation of mitogen- activated protein kinase (MAPK) signaling molecules such as extracellular signal-regulated kinase (ERK) 1/2, p38 MAPK and c-Jun N-terminal kinases (JNK).	beta-thujaplicin	0-10	mitogen-activated protein kinase 1	Mus musculus	156-160
25449038-5	2015	Hinokitiol appeared to achieve this effect by reducing the expression of MMP-1 and by suppressing the phosphorylation of mitogen- activated protein kinase (MAPK) signaling molecules such as extracellular signal-regulated kinase (ERK) 1/2, p38 MAPK and c-Jun N-terminal kinases (JNK).	beta-thujaplicin	0-10	mitogen-activated protein kinase 3	Mus musculus	190-237
25449038-5	2015	Hinokitiol appeared to achieve this effect by reducing the expression of MMP-1 and by suppressing the phosphorylation of mitogen- activated protein kinase (MAPK) signaling molecules such as extracellular signal-regulated kinase (ERK) 1/2, p38 MAPK and c-Jun N-terminal kinases (JNK).	beta-thujaplicin	0-10	mitogen-activated protein kinase 14	Mus musculus	239-247
25449038-5	2015	Hinokitiol appeared to achieve this effect by reducing the expression of MMP-1 and by suppressing the phosphorylation of mitogen- activated protein kinase (MAPK) signaling molecules such as extracellular signal-regulated kinase (ERK) 1/2, p38 MAPK and c-Jun N-terminal kinases (JNK).	beta-thujaplicin	0-10	jun proto-oncogene	Mus musculus	252-257
25449038-6	2015	On the other hand, hinokitiol treatment reversed IkappaB-alpha degradation and inhibited the phosphorylation of p65 nuclear factor kappa B (NF-kappaB) and cJun in B16-F10 cells.	beta-thujaplicin	19-29	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	49-62
25449038-6	2015	On the other hand, hinokitiol treatment reversed IkappaB-alpha degradation and inhibited the phosphorylation of p65 nuclear factor kappa B (NF-kappaB) and cJun in B16-F10 cells.	beta-thujaplicin	19-29	jun proto-oncogene	Mus musculus	155-159
25449038-7	2015	In addition, hinokitiol suppressed the translocation of p65 NF-kappaB from the cytosol to the nucleus, suggesting reduced NF-kappaB activation.	beta-thujaplicin	13-23	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	56-69
26379747-10	2015	In conclusion, we for the first time demonstrated that hinokitiol upregulates p21 expression and attenuates IFN-gamma secretion in ConA-stimulated T lymphocytes, thereby arresting cell cycle at the G0/G1 phase.	beta-thujaplicin	55-65	H3 histone pseudogene 16	Homo sapiens	78-81
25666914-2	2015	In this study, we found that beta-thujaplicin significantly suppressed the proliferation through arresting the cell cycle transition from G1 to S phase as well as inhibited the expression of cell cycle-related proteins, cyclin D1, and cyclin-dependent kinase 4 (CDK4) in MCF-7 and T47D luminal subtype breast cancer cells.	beta-thujaplicin	29-45	cyclin D1	Homo sapiens	220-229
25666914-2	2015	In this study, we found that beta-thujaplicin significantly suppressed the proliferation through arresting the cell cycle transition from G1 to S phase as well as inhibited the expression of cell cycle-related proteins, cyclin D1, and cyclin-dependent kinase 4 (CDK4) in MCF-7 and T47D luminal subtype breast cancer cells.	beta-thujaplicin	29-45	cyclin dependent kinase 4	Homo sapiens	235-260
25666914-2	2015	In this study, we found that beta-thujaplicin significantly suppressed the proliferation through arresting the cell cycle transition from G1 to S phase as well as inhibited the expression of cell cycle-related proteins, cyclin D1, and cyclin-dependent kinase 4 (CDK4) in MCF-7 and T47D luminal subtype breast cancer cells.	beta-thujaplicin	29-45	cyclin dependent kinase 4	Homo sapiens	262-266
25666914-3	2015	In addition, estrogen receptor alpha (ER-alpha) was down-regulated by beta-thujaplicin via enhanced proteolysis by ubiquitination, which led to cell growth inhibition.	beta-thujaplicin	70-86	estrogen receptor 1	Homo sapiens	13-36
25666914-3	2015	In addition, estrogen receptor alpha (ER-alpha) was down-regulated by beta-thujaplicin via enhanced proteolysis by ubiquitination, which led to cell growth inhibition.	beta-thujaplicin	70-86	estrogen receptor 1	Homo sapiens	38-46
26379747-10	2015	In conclusion, we for the first time demonstrated that hinokitiol upregulates p21 expression and attenuates IFN-gamma secretion in ConA-stimulated T lymphocytes, thereby arresting cell cycle at the G0/G1 phase.	beta-thujaplicin	55-65	interferon gamma	Homo sapiens	108-117
25169829-7	2014	RESULTS: Hinokitiol inhibited IL-1beta-stimulated MMP-1,-3 and -13 expressions and IL-1beta-induced activation of intracellular beta-catenin proteins in cultured chondrocytes.	beta-thujaplicin	9-19	interleukin 1 beta	Rattus norvegicus	30-38
25169829-7	2014	RESULTS: Hinokitiol inhibited IL-1beta-stimulated MMP-1,-3 and -13 expressions and IL-1beta-induced activation of intracellular beta-catenin proteins in cultured chondrocytes.	beta-thujaplicin	9-19	interleukin 1 beta	Rattus norvegicus	83-91
25169829-7	2014	RESULTS: Hinokitiol inhibited IL-1beta-stimulated MMP-1,-3 and -13 expressions and IL-1beta-induced activation of intracellular beta-catenin proteins in cultured chondrocytes.	beta-thujaplicin	9-19	catenin beta 1	Rattus norvegicus	128-140
25169829-9	2014	CONCLUSIONS: Hinokitiol is an effective anti-inflammatory reagent that acts by inhibiting the Wnt/beta-catenin signaling pathway and could be a promising therapeutic agent for the prevention and treatment of osteoarthritis.	beta-thujaplicin	13-23	Wnt family member 2	Rattus norvegicus	94-97
25169829-9	2014	CONCLUSIONS: Hinokitiol is an effective anti-inflammatory reagent that acts by inhibiting the Wnt/beta-catenin signaling pathway and could be a promising therapeutic agent for the prevention and treatment of osteoarthritis.	beta-thujaplicin	13-23	catenin beta 1	Rattus norvegicus	98-110
22419431-9	2012	Results showed that UVB-induced MMP-1 production was suppressed by the beta-thujaplicin treatment in a dose-dependent manner, but not by vitamin C and vitamin E.	beta-thujaplicin	71-87	matrix metallopeptidase 1	Homo sapiens	32-37
23473801-5	2013	In the present study, hinokitiol (1 and 2 muM) inhibited the collagen-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and ADP.	beta-thujaplicin	22-32	latexin	Homo sapiens	42-45
23473801-6	2013	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)gamma2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH ) formation.	beta-thujaplicin	0-10	phospholipase C gamma 2	Homo sapiens	61-71
23473801-6	2013	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)gamma2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH ) formation.	beta-thujaplicin	0-10	AKT serine/threonine kinase 1	Homo sapiens	144-147
23473801-10	2013	In conclusion, hinokitiol may inhibit platelet activation by inhibiting the PLCgamma2-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt.	beta-thujaplicin	15-25	AKT serine/threonine kinase 1	Homo sapiens	182-185
25105411-8	2014	In summary, we demonstrated novel mechanisms by which hinokitiol, an essential oil extract, acted as a promising anticancer agent to overcome EGFR-TKI resistance in lung cancer cells via inducing DNA damage, autophagy, cell cycle arrest, and senescence in vitro and in vivo.	beta-thujaplicin	54-64	epidermal growth factor receptor	Homo sapiens	142-146
24370180-4	2014	The extracellular-signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) pathways are involved in hinokitiol-induced HIF-1alpha protein expression in dental pulp cells.	beta-thujaplicin	121-131	mitogen-activated protein kinase 1	Homo sapiens	4-41
24370180-4	2014	The extracellular-signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) pathways are involved in hinokitiol-induced HIF-1alpha protein expression in dental pulp cells.	beta-thujaplicin	121-131	mitogen-activated protein kinase 1	Homo sapiens	43-46
24370180-4	2014	The extracellular-signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) pathways are involved in hinokitiol-induced HIF-1alpha protein expression in dental pulp cells.	beta-thujaplicin	121-131	mitogen-activated protein kinase 14	Homo sapiens	52-88
24370180-4	2014	The extracellular-signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) pathways are involved in hinokitiol-induced HIF-1alpha protein expression in dental pulp cells.	beta-thujaplicin	121-131	mitogen-activated protein kinase 1	Homo sapiens	90-94
24370180-4	2014	The extracellular-signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) pathways are involved in hinokitiol-induced HIF-1alpha protein expression in dental pulp cells.	beta-thujaplicin	121-131	hypoxia inducible factor 1 subunit alpha	Homo sapiens	140-150
24370180-6	2014	Overall, these results show that hinokitiol promotes ERK and p38MAPK activation and HIF-1alpha-induced VEGF production, thus increasing the angiogenic potential of dental pulp cells.	beta-thujaplicin	33-43	mitogen-activated protein kinase 1	Homo sapiens	53-56
24370180-6	2014	Overall, these results show that hinokitiol promotes ERK and p38MAPK activation and HIF-1alpha-induced VEGF production, thus increasing the angiogenic potential of dental pulp cells.	beta-thujaplicin	33-43	hypoxia inducible factor 1 subunit alpha	Homo sapiens	84-94
24370180-6	2014	Overall, these results show that hinokitiol promotes ERK and p38MAPK activation and HIF-1alpha-induced VEGF production, thus increasing the angiogenic potential of dental pulp cells.	beta-thujaplicin	33-43	vascular endothelial growth factor A	Homo sapiens	103-107
24433214-7	2014	Furthermore, hinokitiol inhibited platelet aggregation and relative [Ca(2+)]i mobilization stimulated by convulxin, an agonist of GP VI, but not by aggretin, an agonist of integrin alpha2beta1, indicating that hinokitiol mediates the inhibition of platelet activation through GP VI, rather than through integrin alpha2beta1.	beta-thujaplicin	13-23	glycoprotein VI platelet	Homo sapiens	130-135
24433214-7	2014	Furthermore, hinokitiol inhibited platelet aggregation and relative [Ca(2+)]i mobilization stimulated by convulxin, an agonist of GP VI, but not by aggretin, an agonist of integrin alpha2beta1, indicating that hinokitiol mediates the inhibition of platelet activation through GP VI, rather than through integrin alpha2beta1.	beta-thujaplicin	13-23	glycoprotein VI platelet	Homo sapiens	276-281
24433214-8	2014	Hinokitiol also specifically inhibited the convulxin-mediated activation of protein kinase C, phospholipase Cgamma2, Akt, mitogen-activated protein kinases, and Lyn.	beta-thujaplicin	0-10	AKT serine/threonine kinase 1	Homo sapiens	117-120
24433214-8	2014	Hinokitiol also specifically inhibited the convulxin-mediated activation of protein kinase C, phospholipase Cgamma2, Akt, mitogen-activated protein kinases, and Lyn.	beta-thujaplicin	0-10	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	161-164
24433214-10	2014	In conclusion, hinokitiol, an antagonist of collagen GP VI may represent a novel antiplatelet drug for the prevention of thrombi associated with coronary and cerebral artery diseases.	beta-thujaplicin	15-25	glycoprotein VI platelet	Homo sapiens	53-58
22419431-10	2012	beta-thujaplicin also prevented the up-regulation of MMP-1 and MMP-3 mRNA.	beta-thujaplicin	0-16	matrix metallopeptidase 1	Homo sapiens	53-58
22419431-10	2012	beta-thujaplicin also prevented the up-regulation of MMP-1 and MMP-3 mRNA.	beta-thujaplicin	0-16	matrix metallopeptidase 3	Homo sapiens	63-68
22419431-13	2012	The IL-6 production induced by UVB was lower in beta-thujaplicin treated fibroblasts than in the controls.	beta-thujaplicin	48-64	interleukin 6	Homo sapiens	4-8
20416277-4	2010	In vitro PHD2 and FIH activity assays based on fluorescence polarization reveal that such HIF-1alpha stabilization is likely medicated by inhibitory effects of hinokitiol on prolyl and asparaginyl hydroxylation of HIF-1alpha.	beta-thujaplicin	160-170	egl-9 family hypoxia inducible factor 1	Homo sapiens	9-13
22507316-13	2012	In agreement with the in vitro study, beta-thujaplicin was shown to be effective in vivo for inhibiting LPS-induced NO and TNF-alpha production and a significant decrease in mortality rate of mice suffering from septic shock was observed.	beta-thujaplicin	38-54	tumor necrosis factor	Mus musculus	123-132
22507316-28	2012	Furthermore, beta-thujaplicin inhibited LPS-induced PGE2, IL-6, and TNF-alpha production as well as iNOS, COX2, and NF-kB protein expression more substantially potent than indomethacin.	beta-thujaplicin	13-29	interleukin 6	Mus musculus	58-62
22507316-28	2012	Furthermore, beta-thujaplicin inhibited LPS-induced PGE2, IL-6, and TNF-alpha production as well as iNOS, COX2, and NF-kB protein expression more substantially potent than indomethacin.	beta-thujaplicin	13-29	tumor necrosis factor	Mus musculus	68-77
22507316-28	2012	Furthermore, beta-thujaplicin inhibited LPS-induced PGE2, IL-6, and TNF-alpha production as well as iNOS, COX2, and NF-kB protein expression more substantially potent than indomethacin.	beta-thujaplicin	13-29	nitric oxide synthase 2, inducible	Mus musculus	100-104
22507316-29	2012	In agreement with the in vitro study, beta-thujaplicin was shown to be effective in vivo for inhibiting LPS-induced NO and TNF-alpha production and a significant decrease in mortality rate of mice suffering from septic shock was observed.	beta-thujaplicin	38-54	tumor necrosis factor	Mus musculus	123-132
20416277-3	2010	Here, we unveil a new action of hinokitiol, an iron chelator found in natural plants, on stabilization of HIF-1alpha in cell cultures in a dose-dependent manner.	beta-thujaplicin	32-42	hypoxia inducible factor 1 subunit alpha	Homo sapiens	106-116
22507316-12	2012	Furthermore, beta-thujaplicin inhibited LPS-induced PGE2, IL-6, and TNF-alpha production as well as iNOS, COX2, and NF- kappaB protein expression more substantially potent than indomethacin.	beta-thujaplicin	13-29	interleukin 6	Mus musculus	58-62
22507316-12	2012	Furthermore, beta-thujaplicin inhibited LPS-induced PGE2, IL-6, and TNF-alpha production as well as iNOS, COX2, and NF- kappaB protein expression more substantially potent than indomethacin.	beta-thujaplicin	13-29	tumor necrosis factor	Mus musculus	68-77
22507316-12	2012	Furthermore, beta-thujaplicin inhibited LPS-induced PGE2, IL-6, and TNF-alpha production as well as iNOS, COX2, and NF- kappaB protein expression more substantially potent than indomethacin.	beta-thujaplicin	13-29	nitric oxide synthase 2, inducible	Mus musculus	100-104
20416277-4	2010	In vitro PHD2 and FIH activity assays based on fluorescence polarization reveal that such HIF-1alpha stabilization is likely medicated by inhibitory effects of hinokitiol on prolyl and asparaginyl hydroxylation of HIF-1alpha.	beta-thujaplicin	160-170	hypoxia inducible factor 1 subunit alpha	Homo sapiens	90-100
20416277-4	2010	In vitro PHD2 and FIH activity assays based on fluorescence polarization reveal that such HIF-1alpha stabilization is likely medicated by inhibitory effects of hinokitiol on prolyl and asparaginyl hydroxylation of HIF-1alpha.	beta-thujaplicin	160-170	hypoxia inducible factor 1 subunit alpha	Homo sapiens	214-224
20416277-5	2010	In addition, the inhibition of PHD2 by hinokitiol is reversed by the addition of 2-OG and iron(II), suggesting that the underlying inhibitory mechanism involves displacement of 2-OG and a chelate formation with iron(II) at the enzyme active site by hinokitiol.	beta-thujaplicin	39-49	egl-9 family hypoxia inducible factor 1	Homo sapiens	31-35
20416277-5	2010	In addition, the inhibition of PHD2 by hinokitiol is reversed by the addition of 2-OG and iron(II), suggesting that the underlying inhibitory mechanism involves displacement of 2-OG and a chelate formation with iron(II) at the enzyme active site by hinokitiol.	beta-thujaplicin	249-259	egl-9 family hypoxia inducible factor 1	Homo sapiens	31-35
19631451-5	2009	In addition, hinokitiol increased the stability of the p27 protein by inhibiting p27 phosphorylation at Thr(187) and by down-regulating Skp2 expression.	beta-thujaplicin	13-23	interferon alpha inducible protein 27	Homo sapiens	55-58
21069157-3	2010	Our results indicate that beta-thujaplicin, diethyldithiocarbamate (DEDTC) and its clinically-used dimer disulfiram, induce insulin-like dose-dependent effects on signalling to FOXO1a in a manner that is strictly dependent on the presence of zinc ions, as other ions including aluminium, cobalt, copper, lithium and manganese cannot substitute.	beta-thujaplicin	26-42	forkhead box O1	Homo sapiens	177-183
19631451-5	2009	In addition, hinokitiol increased the stability of the p27 protein by inhibiting p27 phosphorylation at Thr(187) and by down-regulating Skp2 expression.	beta-thujaplicin	13-23	interferon alpha inducible protein 27	Homo sapiens	81-84
19631451-5	2009	In addition, hinokitiol increased the stability of the p27 protein by inhibiting p27 phosphorylation at Thr(187) and by down-regulating Skp2 expression.	beta-thujaplicin	13-23	S-phase kinase associated protein 2	Homo sapiens	136-140
16781122-7	2006	These results suggest that hinokitiol-induced ERK phosphorylation reduces MITF and TYR transcription, and mediates the action of hinokitiol on melanogenesis.	beta-thujaplicin	27-37	tyrosinase	Mus musculus	83-86
18537078-0	2008	Hinokitiol, a natural tropolone derivative, inhibits TNF-alpha production in LPS-activated macrophages via suppression of NF-kappaB.	beta-thujaplicin	0-10	tumor necrosis factor	Mus musculus	53-62
18537078-0	2008	Hinokitiol, a natural tropolone derivative, inhibits TNF-alpha production in LPS-activated macrophages via suppression of NF-kappaB.	beta-thujaplicin	0-10	toll-like receptor 4	Mus musculus	77-80
18537078-0	2008	Hinokitiol, a natural tropolone derivative, inhibits TNF-alpha production in LPS-activated macrophages via suppression of NF-kappaB.	beta-thujaplicin	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	122-131
17055455-0	2006	Hinokitiol, a metal chelator derived from natural plants, suppresses cell growth and disrupts androgen receptor signaling in prostate carcinoma cell lines.	beta-thujaplicin	0-10	androgen receptor	Homo sapiens	94-111
16781122-4	2006	RESULTS: Hinokitiol markedly inhibited melanin synthesis and also reduced the protein levels of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP-1), tyrosinase-related protein 2 (TYRP-2) and MITF in Mel-Ab cells.	beta-thujaplicin	9-19	tyrosinase	Mus musculus	96-106
16781122-4	2006	RESULTS: Hinokitiol markedly inhibited melanin synthesis and also reduced the protein levels of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP-1), tyrosinase-related protein 2 (TYRP-2) and MITF in Mel-Ab cells.	beta-thujaplicin	9-19	tyrosinase	Mus musculus	108-111
16781122-10	2006	CONCLUSION: Therefore, we suggest that TYRP-1 and TYRP-2 may be regulated by post-translational degradation after hinokitiol treatment.	beta-thujaplicin	114-124	tyrosinase-related protein 1	Mus musculus	39-45
16781122-4	2006	RESULTS: Hinokitiol markedly inhibited melanin synthesis and also reduced the protein levels of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP-1), tyrosinase-related protein 2 (TYRP-2) and MITF in Mel-Ab cells.	beta-thujaplicin	9-19	tyrosinase-related protein 1	Mus musculus	114-142
16781122-4	2006	RESULTS: Hinokitiol markedly inhibited melanin synthesis and also reduced the protein levels of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP-1), tyrosinase-related protein 2 (TYRP-2) and MITF in Mel-Ab cells.	beta-thujaplicin	9-19	tyrosinase-related protein 1	Mus musculus	144-150
16781122-10	2006	CONCLUSION: Therefore, we suggest that TYRP-1 and TYRP-2 may be regulated by post-translational degradation after hinokitiol treatment.	beta-thujaplicin	114-124	dopachrome tautomerase	Mus musculus	50-56
16781122-4	2006	RESULTS: Hinokitiol markedly inhibited melanin synthesis and also reduced the protein levels of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP-1), tyrosinase-related protein 2 (TYRP-2) and MITF in Mel-Ab cells.	beta-thujaplicin	9-19	dopachrome tautomerase	Mus musculus	153-181
16781122-4	2006	RESULTS: Hinokitiol markedly inhibited melanin synthesis and also reduced the protein levels of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP-1), tyrosinase-related protein 2 (TYRP-2) and MITF in Mel-Ab cells.	beta-thujaplicin	9-19	dopachrome tautomerase	Mus musculus	183-189
16171776-6	2005	Attempts have been made to find isozyme-specific inhibitors of 12-lipoxygenase, and earlier we found hinokitiol, a tropolone, as a potent inhibitor selective for the platelet-type 12-lipoxygenase.	beta-thujaplicin	101-111	arachidonate 12-lipoxygenase, 12S type	Homo sapiens	166-195
16781122-4	2006	RESULTS: Hinokitiol markedly inhibited melanin synthesis and also reduced the protein levels of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP-1), tyrosinase-related protein 2 (TYRP-2) and MITF in Mel-Ab cells.	beta-thujaplicin	9-19	melanogenesis associated transcription factor	Mus musculus	195-199
16781122-5	2006	In addition, hinokitiol significantly increased the phosphorylations of extracellular signal-regulated kinases 1 and 2 (ERK1/2).	beta-thujaplicin	13-23	mitogen-activated protein kinase 3	Mus musculus	72-118
16781122-5	2006	In addition, hinokitiol significantly increased the phosphorylations of extracellular signal-regulated kinases 1 and 2 (ERK1/2).	beta-thujaplicin	13-23	mitogen-activated protein kinase 3	Mus musculus	120-126
16781122-7	2006	These results suggest that hinokitiol-induced ERK phosphorylation reduces MITF and TYR transcription, and mediates the action of hinokitiol on melanogenesis.	beta-thujaplicin	27-37	melanogenesis associated transcription factor	Mus musculus	74-78
16327152-8	2005	Moreover, 4-n-butylresorcinol showed an additive effect in combination with hinokitiol, which reduces MITF expression.	beta-thujaplicin	76-86	melanogenesis associated transcription factor	Mus musculus	102-106
15089040-0	2004	(-)-Epigallocatechin-3-gallate and hinokitiol reduce melanin synthesis via decreased MITF production.	beta-thujaplicin	35-45	melanocyte inducing transcription factor	Homo sapiens	85-89
15089040-7	2004	On the other hand, both EGCG and hinokitiol reduced the protein levels of MITF and of tyrosinase, the rate limiting melanogenic enzyme, whereas kojic acid had no effect.	beta-thujaplicin	33-43	melanocyte inducing transcription factor	Homo sapiens	74-78
15089040-7	2004	On the other hand, both EGCG and hinokitiol reduced the protein levels of MITF and of tyrosinase, the rate limiting melanogenic enzyme, whereas kojic acid had no effect.	beta-thujaplicin	33-43	tyrosinase	Homo sapiens	86-96
15089040-8	2004	In addition, hinokitiol strongly downregulated the activity of tyrosinase, whereas EGCG or kojic acid had only a little effect.	beta-thujaplicin	13-23	tyrosinase	Homo sapiens	63-73
15089040-9	2004	These results show that both EGCG and hinokitiol reduce MITF production, and suggest that reduced tyrosinase activity by hinokitiol explains their synergistic effect on melanogenesis.	beta-thujaplicin	38-48	melanocyte inducing transcription factor	Homo sapiens	56-60
33809876-6	2021	As a result of screening, we obtained three molecules (hinokitiol, preussomerin C, and tanshinone I) that could be considered senolytic compound candidates since they share similarities in structure with senolytic leads (tunicamycin, ginsenoside Rb1, ABT 737, rapamycin, navitoclax, timosaponin A-III, digoxin, roxithromycin, and azithromycin) and targets involved in senescence pathways with potential use in the treatment of age-related diseases.	beta-thujaplicin	55-65	RB transcriptional corepressor 1	Homo sapiens	246-249
10371304-0	1999	Induction of apoptosis by hinokitiol, a potent iron chelator, in teratocarcinoma F9 cells is mediated through the activation of caspase-3.	beta-thujaplicin	26-36	caspase 3	Homo sapiens	128-137
10371304-7	1999	Caspase-3, one of the key enzymes in the apoptotic cascade, was specifically activated by hinokitiol treatment, but not by the other two derivatives.	beta-thujaplicin	90-100	caspase 3	Homo sapiens	0-9
10371304-9	1999	These results indicate that iron deprivation by hinokitiol can induce apoptosis of F9 cells through the activation of caspase-3.	beta-thujaplicin	48-58	caspase 3	Homo sapiens	118-127
9424082-9	1998	Topical application of beta-thujaplicin decreased the number of ultraviolet B-mediated sunburn cells and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end labeling-positive cells in mouse ear skin.	beta-thujaplicin	23-39	deoxynucleotidyltransferase, terminal	Mus musculus	105-142
9424082-9	1998	Topical application of beta-thujaplicin decreased the number of ultraviolet B-mediated sunburn cells and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end labeling-positive cells in mouse ear skin.	beta-thujaplicin	23-39	deoxynucleotidyltransferase, terminal	Mus musculus	144-147
34536557-0	2022	Hinokitiol-induced decreases of tyrosinase and microphthalmia-associated transcription factor are mediated by the endoplasmic reticulum-associated degradation pathway in human melanoma cells.	beta-thujaplicin	0-10	tyrosinase	Homo sapiens	32-42
34536557-0	2022	Hinokitiol-induced decreases of tyrosinase and microphthalmia-associated transcription factor are mediated by the endoplasmic reticulum-associated degradation pathway in human melanoma cells.	beta-thujaplicin	0-10	melanocyte inducing transcription factor	Homo sapiens	47-93
34536557-2	2022	We previously showed that hinokitiol, a naturally occurring seven-membered ring terpenoid, potently inhibits human TYR activity.	beta-thujaplicin	26-36	tyrosinase	Homo sapiens	115-118
34536557-3	2022	Interestingly, hinokitiol was recently reported to decrease expression of TYR and microphthalmia-associated transcription factor (MITF), which is a main transcription factor of the TYR gene, in murine melanoma cells.	beta-thujaplicin	15-25	tyrosinase	Homo sapiens	74-77
34361036-0	2021	Hinokitiol Exhibits Antitumor Properties through Induction of ROS-Mediated Apoptosis and p53-Driven Cell-Cycle Arrest in Endometrial Cancer Cell Lines (Ishikawa, HEC-1A, KLE).	beta-thujaplicin	0-10	tumor protein p53	Homo sapiens	89-92
34536557-3	2022	Interestingly, hinokitiol was recently reported to decrease expression of TYR and microphthalmia-associated transcription factor (MITF), which is a main transcription factor of the TYR gene, in murine melanoma cells.	beta-thujaplicin	15-25	melanogenesis associated transcription factor	Mus musculus	82-128
34536557-3	2022	Interestingly, hinokitiol was recently reported to decrease expression of TYR and microphthalmia-associated transcription factor (MITF), which is a main transcription factor of the TYR gene, in murine melanoma cells.	beta-thujaplicin	15-25	melanogenesis associated transcription factor	Mus musculus	130-134
34536557-3	2022	Interestingly, hinokitiol was recently reported to decrease expression of TYR and microphthalmia-associated transcription factor (MITF), which is a main transcription factor of the TYR gene, in murine melanoma cells.	beta-thujaplicin	15-25	tyrosinase	Homo sapiens	181-184
34536557-4	2022	However, the mechanisms by which hinokitiol decreases the intracellular levels of TYR and MITF have not been fully elucidated.	beta-thujaplicin	33-43	tyrosinase	Homo sapiens	82-85
34536557-4	2022	However, the mechanisms by which hinokitiol decreases the intracellular levels of TYR and MITF have not been fully elucidated.	beta-thujaplicin	33-43	melanogenesis associated transcription factor	Mus musculus	90-94
34536557-6	2022	As a result, hinokitiol treatment decreased TYR protein level in a time- and dose-dependent manner in G361 human melanoma cells, while MITF protein level was decreased only at higher concentrations after 3 days treatment.	beta-thujaplicin	13-23	tyrosinase	Homo sapiens	44-47
34536557-6	2022	As a result, hinokitiol treatment decreased TYR protein level in a time- and dose-dependent manner in G361 human melanoma cells, while MITF protein level was decreased only at higher concentrations after 3 days treatment.	beta-thujaplicin	13-23	melanocyte inducing transcription factor	Homo sapiens	135-139
34536557-7	2022	Notably, the mRNA levels of TYR and MITF were slightly increased by hinokitiol treatment.	beta-thujaplicin	68-78	tyrosinase	Homo sapiens	28-31
34536557-7	2022	Notably, the mRNA levels of TYR and MITF were slightly increased by hinokitiol treatment.	beta-thujaplicin	68-78	melanocyte inducing transcription factor	Homo sapiens	36-40
34536557-9	2022	Importantly, co-treatment of ERAD inhibitor with hinokitiol restored the protein levels of TYR and MITF to approximately 30% and 20% of total those in untreated control cells, respectively.	beta-thujaplicin	49-59	tyrosinase	Homo sapiens	91-94
34536557-9	2022	Importantly, co-treatment of ERAD inhibitor with hinokitiol restored the protein levels of TYR and MITF to approximately 30% and 20% of total those in untreated control cells, respectively.	beta-thujaplicin	49-59	melanocyte inducing transcription factor	Homo sapiens	99-103
34536557-10	2022	Hinokitiol affected the ER homeostasis as well as degradation of TYR and MITF in two human melanoma cell lines, G361 and HT-144, but the changes of ER-stress markers under the hinokitiol treatment were different in the two human melanoma cell lines.	beta-thujaplicin	0-10	tyrosinase	Homo sapiens	65-68
34536557-10	2022	Hinokitiol affected the ER homeostasis as well as degradation of TYR and MITF in two human melanoma cell lines, G361 and HT-144, but the changes of ER-stress markers under the hinokitiol treatment were different in the two human melanoma cell lines.	beta-thujaplicin	0-10	melanocyte inducing transcription factor	Homo sapiens	73-77
34536557-11	2022	Taken together, these observations indicate that hinokitiol may induce ER stress and trigger the degradation of unfolded newly synthesizing TYR and MITF via the ERAD pathway.	beta-thujaplicin	49-59	tyrosinase	Homo sapiens	140-143
34536557-11	2022	Taken together, these observations indicate that hinokitiol may induce ER stress and trigger the degradation of unfolded newly synthesizing TYR and MITF via the ERAD pathway.	beta-thujaplicin	49-59	melanocyte inducing transcription factor	Homo sapiens	148-152
34436874-1	2021	Tris-chelate complexes of Co(III), Rh(III), and Ir(III) with 4-isopropyltropolone (hinokitiol or beta-thujaplicin) form by the substitution of carbonate and chloride ligands from group 9 trivalent metal salts.	beta-thujaplicin	61-81	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	26-33
34436874-1	2021	Tris-chelate complexes of Co(III), Rh(III), and Ir(III) with 4-isopropyltropolone (hinokitiol or beta-thujaplicin) form by the substitution of carbonate and chloride ligands from group 9 trivalent metal salts.	beta-thujaplicin	61-81	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	38-41
34436874-1	2021	Tris-chelate complexes of Co(III), Rh(III), and Ir(III) with 4-isopropyltropolone (hinokitiol or beta-thujaplicin) form by the substitution of carbonate and chloride ligands from group 9 trivalent metal salts.	beta-thujaplicin	61-81	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	51-54
34436874-1	2021	Tris-chelate complexes of Co(III), Rh(III), and Ir(III) with 4-isopropyltropolone (hinokitiol or beta-thujaplicin) form by the substitution of carbonate and chloride ligands from group 9 trivalent metal salts.	beta-thujaplicin	83-93	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	26-33
34436874-1	2021	Tris-chelate complexes of Co(III), Rh(III), and Ir(III) with 4-isopropyltropolone (hinokitiol or beta-thujaplicin) form by the substitution of carbonate and chloride ligands from group 9 trivalent metal salts.	beta-thujaplicin	83-93	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	38-41
34436874-1	2021	Tris-chelate complexes of Co(III), Rh(III), and Ir(III) with 4-isopropyltropolone (hinokitiol or beta-thujaplicin) form by the substitution of carbonate and chloride ligands from group 9 trivalent metal salts.	beta-thujaplicin	83-93	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	51-54
34436874-1	2021	Tris-chelate complexes of Co(III), Rh(III), and Ir(III) with 4-isopropyltropolone (hinokitiol or beta-thujaplicin) form by the substitution of carbonate and chloride ligands from group 9 trivalent metal salts.	beta-thujaplicin	97-113	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	26-33
34436874-1	2021	Tris-chelate complexes of Co(III), Rh(III), and Ir(III) with 4-isopropyltropolone (hinokitiol or beta-thujaplicin) form by the substitution of carbonate and chloride ligands from group 9 trivalent metal salts.	beta-thujaplicin	97-113	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	38-41
34436874-1	2021	Tris-chelate complexes of Co(III), Rh(III), and Ir(III) with 4-isopropyltropolone (hinokitiol or beta-thujaplicin) form by the substitution of carbonate and chloride ligands from group 9 trivalent metal salts.	beta-thujaplicin	97-113	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	51-54
34361036-5	2021	Hinokitiol significantly suppressed cell proliferation through the inhibition of the expression of cell-cycle mediators, such as cyclin D1 and cyclin-dependent kinase 4 (CDK4), as well as the induction of the tumor suppressor protein p53.	beta-thujaplicin	0-10	cyclin D1	Homo sapiens	129-138
34361036-5	2021	Hinokitiol significantly suppressed cell proliferation through the inhibition of the expression of cell-cycle mediators, such as cyclin D1 and cyclin-dependent kinase 4 (CDK4), as well as the induction of the tumor suppressor protein p53.	beta-thujaplicin	0-10	cyclin dependent kinase 4	Homo sapiens	143-168
34361036-5	2021	Hinokitiol significantly suppressed cell proliferation through the inhibition of the expression of cell-cycle mediators, such as cyclin D1 and cyclin-dependent kinase 4 (CDK4), as well as the induction of the tumor suppressor protein p53.	beta-thujaplicin	0-10	cyclin dependent kinase 4	Homo sapiens	170-174
34361036-5	2021	Hinokitiol significantly suppressed cell proliferation through the inhibition of the expression of cell-cycle mediators, such as cyclin D1 and cyclin-dependent kinase 4 (CDK4), as well as the induction of the tumor suppressor protein p53.	beta-thujaplicin	0-10	tumor protein p53	Homo sapiens	234-237
34361036-6	2021	In addition, hinokitiol increased the number of apoptotic cells and increased the protein expression of cleaved-poly-ADP-ribose polymerase (PARP) and active cleaved-caspase-3, as well as the ratio of Bcl-2-associated X protein (Bax) to B-cell lymphoma 2 (Bcl-2).	beta-thujaplicin	13-23	poly(ADP-ribose) polymerase 1	Homo sapiens	104-138
34361036-6	2021	In addition, hinokitiol increased the number of apoptotic cells and increased the protein expression of cleaved-poly-ADP-ribose polymerase (PARP) and active cleaved-caspase-3, as well as the ratio of Bcl-2-associated X protein (Bax) to B-cell lymphoma 2 (Bcl-2).	beta-thujaplicin	13-23	poly(ADP-ribose) polymerase 1	Homo sapiens	140-144
34361036-6	2021	In addition, hinokitiol increased the number of apoptotic cells and increased the protein expression of cleaved-poly-ADP-ribose polymerase (PARP) and active cleaved-caspase-3, as well as the ratio of Bcl-2-associated X protein (Bax) to B-cell lymphoma 2 (Bcl-2).	beta-thujaplicin	13-23	BCL2 associated X, apoptosis regulator	Homo sapiens	200-226
34361036-6	2021	In addition, hinokitiol increased the number of apoptotic cells and increased the protein expression of cleaved-poly-ADP-ribose polymerase (PARP) and active cleaved-caspase-3, as well as the ratio of Bcl-2-associated X protein (Bax) to B-cell lymphoma 2 (Bcl-2).	beta-thujaplicin	13-23	BCL2 associated X, apoptosis regulator	Homo sapiens	228-231
34361036-6	2021	In addition, hinokitiol increased the number of apoptotic cells and increased the protein expression of cleaved-poly-ADP-ribose polymerase (PARP) and active cleaved-caspase-3, as well as the ratio of Bcl-2-associated X protein (Bax) to B-cell lymphoma 2 (Bcl-2).	beta-thujaplicin	13-23	BCL2 apoptosis regulator	Homo sapiens	236-253
34361036-6	2021	In addition, hinokitiol increased the number of apoptotic cells and increased the protein expression of cleaved-poly-ADP-ribose polymerase (PARP) and active cleaved-caspase-3, as well as the ratio of Bcl-2-associated X protein (Bax) to B-cell lymphoma 2 (Bcl-2).	beta-thujaplicin	13-23	BCL2 apoptosis regulator	Homo sapiens	255-260
34361036-7	2021	Interestingly, except for KLE cells, hinokitiol induced autophagy by promoting the accumulation of the microtubule-associated protein light chain 3B (LC3B) and reducing the sequestosome-1 (p62/SQSTM1) protein level.	beta-thujaplicin	37-47	microtubule associated protein 1 light chain 3 beta	Homo sapiens	150-154
34361036-7	2021	Interestingly, except for KLE cells, hinokitiol induced autophagy by promoting the accumulation of the microtubule-associated protein light chain 3B (LC3B) and reducing the sequestosome-1 (p62/SQSTM1) protein level.	beta-thujaplicin	37-47	sequestosome 1	Homo sapiens	173-187
34361036-7	2021	Interestingly, except for KLE cells, hinokitiol induced autophagy by promoting the accumulation of the microtubule-associated protein light chain 3B (LC3B) and reducing the sequestosome-1 (p62/SQSTM1) protein level.	beta-thujaplicin	37-47	sequestosome 1	Homo sapiens	189-192
34361036-7	2021	Interestingly, except for KLE cells, hinokitiol induced autophagy by promoting the accumulation of the microtubule-associated protein light chain 3B (LC3B) and reducing the sequestosome-1 (p62/SQSTM1) protein level.	beta-thujaplicin	37-47	sequestosome 1	Homo sapiens	193-199
34361036-8	2021	Furthermore, hinokitiol triggered ROS production and upregulated the phosphorylation of extracellular-signal-regulated kinase (p-ERK1/2) in EC cells.	beta-thujaplicin	13-23	mitogen-activated protein kinase 3	Homo sapiens	129-135
34199423-0	2021	beta-Thujaplicin Enhances TRAIL-Induced Apoptosis via the Dual Effects of XIAP Inhibition and Degradation in NCI-H460 Human Lung Cancer Cells.	beta-thujaplicin	0-16	TNF superfamily member 10	Homo sapiens	26-31
34199423-0	2021	beta-Thujaplicin Enhances TRAIL-Induced Apoptosis via the Dual Effects of XIAP Inhibition and Degradation in NCI-H460 Human Lung Cancer Cells.	beta-thujaplicin	0-16	X-linked inhibitor of apoptosis	Homo sapiens	74-78
34199423-3	2021	Methods: Trypan blue staining, a WST-8 assay, and a caspase-3/7 activity assay were used to investigate whether beta-thujaplicin sensitizes cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis.	beta-thujaplicin	112-128	TNF superfamily member 10	Homo sapiens	195-200
34199423-4	2021	Additionally, western blotting was performed to clarify the effects of beta-thujaplicin on X-linked inhibitor of apoptosis protein (XIAP) in NCI-H460 cells and a fluorescence polarization binding assay was used to evaluate the binding-inhibitory activity of beta-thujaplicin against XIAP-BIR3.	beta-thujaplicin	71-87	X-linked inhibitor of apoptosis	Homo sapiens	91-130
34199423-4	2021	Additionally, western blotting was performed to clarify the effects of beta-thujaplicin on X-linked inhibitor of apoptosis protein (XIAP) in NCI-H460 cells and a fluorescence polarization binding assay was used to evaluate the binding-inhibitory activity of beta-thujaplicin against XIAP-BIR3.	beta-thujaplicin	71-87	X-linked inhibitor of apoptosis	Homo sapiens	132-136
34199423-4	2021	Additionally, western blotting was performed to clarify the effects of beta-thujaplicin on X-linked inhibitor of apoptosis protein (XIAP) in NCI-H460 cells and a fluorescence polarization binding assay was used to evaluate the binding-inhibitory activity of beta-thujaplicin against XIAP-BIR3.	beta-thujaplicin	258-274	X-linked inhibitor of apoptosis	Homo sapiens	283-287
34199423-6	2021	beta-thujaplicin significantly potentiated the apoptosis induction effect of TRAIL on NCI-H460 cells, which was accompanied by enhanced caspase-3/7 activity.	beta-thujaplicin	0-16	TNF superfamily member 10	Homo sapiens	77-82
34199423-6	2021	beta-thujaplicin significantly potentiated the apoptosis induction effect of TRAIL on NCI-H460 cells, which was accompanied by enhanced caspase-3/7 activity.	beta-thujaplicin	0-16	caspase 3	Homo sapiens	136-147
34199423-7	2021	Interestingly, beta-thujaplicin treatment in NCI-H460 cells decreased XIAP levels.	beta-thujaplicin	15-31	X-linked inhibitor of apoptosis	Homo sapiens	70-74
34199423-8	2021	Furthermore, beta-thujaplicin was able to bind XIAP-BIR3 at the Smac binding site.	beta-thujaplicin	13-29	X-linked inhibitor of apoptosis	Homo sapiens	47-51
34199423-8	2021	Furthermore, beta-thujaplicin was able to bind XIAP-BIR3 at the Smac binding site.	beta-thujaplicin	13-29	diablo IAP-binding mitochondrial protein	Homo sapiens	64-68
34199423-9	2021	Conclusions: These findings indicate that beta-thujaplicin could enhance TRAIL-induced apoptosis in NCI-H460 cells via XIAP inhibition and degradation.	beta-thujaplicin	42-58	TNF superfamily member 10	Homo sapiens	73-78
34199423-9	2021	Conclusions: These findings indicate that beta-thujaplicin could enhance TRAIL-induced apoptosis in NCI-H460 cells via XIAP inhibition and degradation.	beta-thujaplicin	42-58	X-linked inhibitor of apoptosis	Homo sapiens	119-123
35399709-0	2022	Hinokitiol impedes tumor drug resistance by suppressing protein kinase B/mammalian targets of rapamycin axis.	beta-thujaplicin	0-10	protein tyrosine kinase 2 beta	Homo sapiens	56-72
35399709-6	2022	Here, we showed that hinokitiol dose-dependently decreased P-gp expression and suppressed the P-gp-driven efflux activity based on Rhodamine 123 assay.	beta-thujaplicin	21-31	ATP binding cassette subfamily B member 1	Homo sapiens	59-63
35399709-6	2022	Here, we showed that hinokitiol dose-dependently decreased P-gp expression and suppressed the P-gp-driven efflux activity based on Rhodamine 123 assay.	beta-thujaplicin	21-31	ATP binding cassette subfamily B member 1	Homo sapiens	94-98
35399709-8	2022	The transfection of cells with active P-AKT rescued hinokitiol-induced downregulation of P-gp, suggesting the involvement of Akt/mTOR/p70s6K signaling in P-gp expression.	beta-thujaplicin	52-62	ATP binding cassette subfamily B member 1	Homo sapiens	89-93
35399709-8	2022	The transfection of cells with active P-AKT rescued hinokitiol-induced downregulation of P-gp, suggesting the involvement of Akt/mTOR/p70s6K signaling in P-gp expression.	beta-thujaplicin	52-62	AKT serine/threonine kinase 1	Homo sapiens	125-128
35399709-8	2022	The transfection of cells with active P-AKT rescued hinokitiol-induced downregulation of P-gp, suggesting the involvement of Akt/mTOR/p70s6K signaling in P-gp expression.	beta-thujaplicin	52-62	mechanistic target of rapamycin kinase	Homo sapiens	129-133
35399709-8	2022	The transfection of cells with active P-AKT rescued hinokitiol-induced downregulation of P-gp, suggesting the involvement of Akt/mTOR/p70s6K signaling in P-gp expression.	beta-thujaplicin	52-62	ribosomal protein S6 kinase B1	Homo sapiens	134-140
35399709-8	2022	The transfection of cells with active P-AKT rescued hinokitiol-induced downregulation of P-gp, suggesting the involvement of Akt/mTOR/p70s6K signaling in P-gp expression.	beta-thujaplicin	52-62	ATP binding cassette subfamily B member 1	Homo sapiens	154-158
35399709-10	2022	These findings indicate that hinokitiol could enhance 5-Fluorouracil therapeutic effects in murine B16F10 and CT26 tumor cells via downregulation of the AKT/mTOR pathway.	beta-thujaplicin	29-39	thymoma viral proto-oncogene 1	Mus musculus	153-156
35399709-10	2022	These findings indicate that hinokitiol could enhance 5-Fluorouracil therapeutic effects in murine B16F10 and CT26 tumor cells via downregulation of the AKT/mTOR pathway.	beta-thujaplicin	29-39	mechanistic target of rapamycin kinase	Mus musculus	157-161
35163553-6	2022	In U-2 OS cells with wild-type tumor suppressor p53, we found that hinokitiol exposure induced p53 expression and cellular senescence, and knockdown of p53 suppressed the senescence.	beta-thujaplicin	67-77	tumor protein p53	Homo sapiens	48-51
35163553-6	2022	In U-2 OS cells with wild-type tumor suppressor p53, we found that hinokitiol exposure induced p53 expression and cellular senescence, and knockdown of p53 suppressed the senescence.	beta-thujaplicin	67-77	tumor protein p53	Homo sapiens	95-98
35163553-7	2022	However, in MG-63 cells with mutated p53, a high percentage of cells underwent apoptosis with cleaved-PARP expression and Annexin V staining after hinokitiol treatment.	beta-thujaplicin	147-157	tumor protein p53	Homo sapiens	37-40
35163553-7	2022	However, in MG-63 cells with mutated p53, a high percentage of cells underwent apoptosis with cleaved-PARP expression and Annexin V staining after hinokitiol treatment.	beta-thujaplicin	147-157	collagen type XI alpha 2 chain	Homo sapiens	102-106
35163553-7	2022	However, in MG-63 cells with mutated p53, a high percentage of cells underwent apoptosis with cleaved-PARP expression and Annexin V staining after hinokitiol treatment.	beta-thujaplicin	147-157	annexin A5	Homo sapiens	122-131
35163553-9	2022	As the autophagy was suppressed through the autophagy inhibitor chloroquine, hinokitiol-induced senescence in U-2 OS cells was significantly enhanced accompanying more abundant p53 expression.	beta-thujaplicin	77-87	tumor protein p53	Homo sapiens	177-180
35090323-8	2022	Furthermore, Hinokitiol significantly inhibited the proliferation of ICC cells by downregulating the ERK and P38 pathways.	beta-thujaplicin	13-23	mitogen-activated protein kinase 1	Mus musculus	101-104
35090323-8	2022	Furthermore, Hinokitiol significantly inhibited the proliferation of ICC cells by downregulating the ERK and P38 pathways.	beta-thujaplicin	13-23	mitogen-activated protein kinase 14	Mus musculus	109-112
35419165-0	2022	Hinokitiol Protects Cardiomyocyte from Oxidative Damage by Inhibiting GSK3beta-Mediated Autophagy.	beta-thujaplicin	0-10	glycogen synthase kinase 3 alpha	Homo sapiens	70-78
35419165-3	2022	Hinokitiol exerts cardioprotective effect through inhibition of GSK-3beta and subsequent elimination of excessive autophagy, tuning autophagic activity in moderate extent for remedial profit in acute myocardial infarction and myocardial ischemia reperfusion injury.	beta-thujaplicin	0-10	glycogen synthase kinase 3 alpha	Homo sapiens	64-73